Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
about
Combining radiotherapy and cancer immunotherapy: a paradigm shiftRecent advances in therapeutic cancer vaccinesTumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated KillingRadiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactionsIdentification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene.Immunological treatment options for locoregionally advanced head and neck squamous cell carcinomaSub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways.Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathwayCombination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.Therapeutic cancer vaccines: current status and moving forward.Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitorsClinical evaluation of TRICOM vector therapeutic cancer vaccinesThe use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killingAttenuated mutant strain of Salmonella Typhimurium lacking the ZnuABC transporter contrasts tumor growth promoting anti-cancer immune response.Role of vaccine therapy in cancer: biology and practiceRole of cytokines in head and neck squamous cell carcinoma.PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.Cancer vaccines: moving beyond current paradigms.Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hostsParadigm shifts in cancer vaccine therapy.Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapyStrategies used for MUC1 immunotherapy: preclinical studies.Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.MUC1 immunotherapy.What role do mucins have in the development of laryngeal squamous cell carcinoma? A systematic review.The clinical implications of antitumor immunity in head and neck cancer.Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence.Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?Immunomodulatory effects of radiation: what is next for cancer therapy?Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy.
P2860
Q27021428-7A0838AD-F0EE-4878-9356-FFF33BC17E51Q27025266-34380B82-4E9A-4B87-8EBF-73597D5E414DQ33275987-C283FCBC-E6D9-4B5D-9A22-44318D16F2ABQ33627023-4CD3F86C-E7D9-4187-A960-28F16226BBA5Q33793930-729B5A2B-C0CE-4D8A-8C56-0CE7F89192B2Q34181954-BF590887-ECD6-497D-AE2F-D168E1F4DD41Q34184469-AD9929C6-B041-4B6B-AEF4-65322EBD3F09Q34444867-36D670E7-9526-4F93-BA68-78AF1A071A31Q34876404-09455605-BF53-4B5F-B31C-DAC1AC78B928Q35594089-45E122FE-B036-4000-9670-93D5CA492106Q35752182-287745D9-DD58-47AE-A082-812580A952DDQ35752201-80121C11-AD33-4FFE-909B-687A016390A4Q35894347-4E127A56-78D8-499B-9C87-A9D8CA28185AQ35922726-0867E605-0D8B-4884-AD1C-6CD227053E5FQ35975387-A8C4342A-8870-4329-BFF4-1CDD28EC16C5Q36099965-8E3B8AD5-AA7E-4DFC-B5CD-0A3083432BB4Q36126003-F1043045-B978-418F-96EE-F042D52BA6FEQ36232119-BB8C900A-9544-4DD3-AB98-E3354C74FF4DQ36256420-34925F78-8D8A-4C7D-AA5C-A8143FC1B737Q36613975-7EFE4598-FD83-4047-8053-8628B9E0E9B1Q36764939-40D1D81D-4A2C-432C-90E6-0702EAB3EBC0Q36868126-5FEC86DF-BF2D-4B83-ADE0-1A945685361CQ36874767-C172B509-56CC-41C1-992B-3069A499C0BEQ37109176-5171A6BE-F91A-4E05-9FD8-5A3C9C2A8E03Q37122893-41C3D780-EF87-4AE1-BC04-CD45E74EA93BQ37193043-C89BE907-9913-48CB-BC0B-2D2D684988B6Q37259594-A46D35C3-B6A0-4AAF-AC24-C93591123691Q37650735-41A06C6B-14F6-4EDF-B7A8-B48A375CDCEBQ37660302-E7973299-6FDA-4EAC-9B50-7F6B908E7136Q37773241-EE321B8B-3590-4A24-9197-BB3E0C6CBBC6Q37869823-8FC4E1FB-92FF-4674-9749-AF2FB344BC7AQ37970005-0CC8D053-74B2-4E6E-9B91-461CCCB9F3E5Q38230278-A100B885-688B-46B8-9294-34C02F80F511Q38247492-51D86646-1ABA-476D-823B-9A8EC732E514Q38404080-3E9B539B-5F37-452F-B597-E8D99899B908Q38549598-50980E3B-723B-48AD-B224-8BC7FD51DE17Q38654155-E5709EE9-F938-427A-928C-F5353769AEBDQ38995718-8A93CA07-583A-4621-90E9-7BC09B0A87E1Q39037817-F9AAFDFD-4AC1-4EED-968D-0EBC1351BD05Q39328588-FBF5F538-0DEE-44DC-B00B-D104CDD2950E
P2860
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Combination chemotherapy and r ...... k augments CTL-mediated lysis.
@ast
Combination chemotherapy and r ...... k augments CTL-mediated lysis.
@en
type
label
Combination chemotherapy and r ...... k augments CTL-mediated lysis.
@ast
Combination chemotherapy and r ...... k augments CTL-mediated lysis.
@en
prefLabel
Combination chemotherapy and r ...... k augments CTL-mediated lysis.
@ast
Combination chemotherapy and r ...... k augments CTL-mediated lysis.
@en
P2093
P2860
P1476
Combination chemotherapy and r ...... ck augments CTL-mediated lysis
@en
P2093
Alexander Gelbard
Charlie T Garnett
Claudia Palena
James W Hodge
Jeffrey Schlom
Kwong-Yok Tsang
Scott I Abrams
Vyomesh Patel
P2860
P304
P356
10.1158/1078-0432.CCR-05-1761
P407
P577
2006-03-01T00:00:00Z